acamprosate vs pimozide
PlainMeds reviewed this comparison against our methodology in August 2026. It places FDA and CMS record fields side by side, without recommending either medication.
Side-by-side comparison of acamprosate and pimozide. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
Campral
Orap
Acamprosate is a medicine that can help you stay away from alcohol if you are alcohol-dependent and have already stopped drinking. It should be used with counseling and support.
Pimozide (Orap) is a medicine that helps control tics in people with Tourette's Disorder. It works by affecting certain chemicals in the brain.
Acamprosate helps people who are alcohol-dependent to not drink alcohol. You must have already stopped drinking before you start taking acamprosate. This medicine works best when it is part of a complete treatment plan that includes counseling and support.
Pimozide is used to treat motor and phonic tics in people with Tourette's Disorder. It is for people who have not had success with other treatments. This medicine is not for tics that are mild or just annoying. It is meant for people whose tics greatly affect their daily life.
Acamprosate is similar to a natural substance in your brain. It is thought to work by helping to restore the normal balance of brain activity that is changed by long-term alcohol use. This can reduce your craving for alcohol.
Pimozide belongs to a class of drugs called antipsychotics. It works by blocking dopamine, a chemical in the brain. By blocking dopamine, pimozide helps to reduce tics.
- • Accidental injury
- • Weakness
- • Pain
- • Loss of appetite
- • Diarrhea
- • Parkinson-like symptoms (tremors, stiffness)
- • Restlessness
- • Muscle stiffness
- • Drowsiness
- Hypotension 14
- Asthenia 13
- Condition Aggravated 13
- Acute Kidney Injury 12
- Coma 12
- Drug Interaction 76
- Parkinsonism 42
- Weight Increased 37
- Somnolence 33
- Hypotension 29
Acamprosate may increase the risk of suicidal thoughts or actions. Your doctor should watch you for depression or suicidal thoughts. Tell your doctor right away if you have any new or worsening symptoms of depression or suicidal thoughts.
Pimozide can cause changes in your heart rhythm (QT prolongation). This can lead to serious heart problems. You should have an ECG (heart test) before starting pimozide and regularly during treatment. Do not take pimozide with other medicines that can also affect your heart rhythm.
Acamprosate may harm your unborn baby. Talk to your doctor if you are pregnant or plan to become pregnant. It is not known if acamprosate passes into breast milk. Talk to your doctor if you are breastfeeding.
Tell your doctor if you are pregnant or plan to become pregnant. It is not known if pimozide will harm your unborn baby. Talk to your doctor about the risks and benefits of taking pimozide during pregnancy and breastfeeding.
Also Compare, Nearby Drugs
Compare pimozide with
How to Read This acamprosate vs pimozide Comparison
acamprosate is classified in the GABA Analog (Alcohol Dependence) drug class, while pimozide sits within the Typical Antipsychotic class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, acamprosate has 64 submissions while pimozide has 217. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. No direct interaction between these two drugs is listed in our FDA-derived dataset, though co-prescription still warrants pharmacist review. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for acamprosate or pimozide.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.